OA11706A - Calcium (3S) tetrahydro-3-furaranyl (1S,2R)-3-[[(4-aminophenyl)sulfony](isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate. - Google Patents

Calcium (3S) tetrahydro-3-furaranyl (1S,2R)-3-[[(4-aminophenyl)sulfony](isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate. Download PDF

Info

Publication number
OA11706A
OA11706A OA1200100016A OA1200100016A OA11706A OA 11706 A OA11706 A OA 11706A OA 1200100016 A OA1200100016 A OA 1200100016A OA 1200100016 A OA1200100016 A OA 1200100016A OA 11706 A OA11706 A OA 11706A
Authority
OA
OAPI
Prior art keywords
compound
formula
preparation
calcium
water
Prior art date
Application number
OA1200100016A
Other languages
English (en)
French (fr)
Inventor
Ian Gordon Armitage
Andrew David Searle
Hardev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA11706A publication Critical patent/OA11706A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA1200100016A 1998-07-18 1999-07-15 Calcium (3S) tetrahydro-3-furaranyl (1S,2R)-3-[[(4-aminophenyl)sulfony](isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate. OA11706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
OA11706A true OA11706A (en) 2005-01-13

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100016A OA11706A (en) 1998-07-18 1999-07-15 Calcium (3S) tetrahydro-3-furaranyl (1S,2R)-3-[[(4-aminophenyl)sulfony](isobutyl) amino]-1-benzyl-2-(phosphonooxy)propylcarbamate.

Country Status (47)

Country Link
US (3) US6514953B1 (is)
EP (2) EP1098898B1 (is)
JP (1) JP3437553B2 (is)
KR (1) KR100694721B1 (is)
CN (1) CN1188422C (is)
AP (1) AP2001002039A0 (is)
AR (1) AR019388A1 (is)
AT (1) ATE229964T1 (is)
AU (1) AU766056B2 (is)
BG (1) BG105253A (is)
BR (1) BRPI9912156B8 (is)
CA (1) CA2337857C (is)
CO (1) CO5090836A1 (is)
CZ (1) CZ300447B6 (is)
DE (1) DE69904600T2 (is)
DK (1) DK1098898T3 (is)
DZ (1) DZ2845A1 (is)
EA (1) EA003191B1 (is)
EE (1) EE200100038A (is)
ES (1) ES2189450T3 (is)
GB (1) GB9815567D0 (is)
GC (1) GC0000105A (is)
GE (1) GEP20033030B (is)
GT (1) GT199900111A (is)
HR (1) HRP20010046A2 (is)
HU (1) HU229700B1 (is)
ID (1) ID28070A (is)
IL (1) IL140824A (is)
IS (1) IS5808A (is)
JO (1) JO2114B1 (is)
MA (1) MA26660A1 (is)
MY (1) MY122323A (is)
NO (1) NO329676B1 (is)
NZ (1) NZ509291A (is)
OA (1) OA11706A (is)
PA (1) PA8477801A1 (is)
PE (1) PE20000869A1 (is)
PL (1) PL195736B1 (is)
PT (1) PT1098898E (is)
SK (1) SK285311B6 (is)
SV (1) SV1999000096A (is)
TN (1) TNSN99145A1 (is)
TR (1) TR200100111T2 (is)
TW (1) TWI245770B (is)
WO (1) WO2000004033A1 (is)
YU (1) YU3401A (is)
ZA (1) ZA200100417B (is)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
WO2001025240A1 (en) * 1999-10-06 2001-04-12 Tibotec Pharmaceuticals Ltd. HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
ES2297467T3 (es) * 2003-09-30 2008-05-01 Tibotec Pharmaceuticals Ltd. Sulfonamidas de inhibicion de vhc.
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2004286239A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
DE602004019815D1 (de) 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituierte carbovir- und abacavir-derivate sowie verwandte verbindungen mit hiv- und hcv-antiviraler wirkung
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
EP1973902A2 (en) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US8598364B2 (en) 2007-03-12 2013-12-03 Nektar Therapeutics Oligomer-protease inhibitor conjugates
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
WO2011001383A1 (en) * 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
CA2774483C (en) * 2009-09-16 2014-11-18 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (en) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Solid state forms of fosamprenavir calcium salt and process for preparation thereof
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US20130211108A1 (en) * 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
IN2012DE00082A (is) 2012-01-10 2015-05-01 Council Scient Ind Res
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
WO1999033792A2 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2000018384A2 (en) * 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
CN1154491C (zh) * 1998-11-04 2004-06-23 法玛西雅厄普约翰美国公司 用于改善替普拉那维的药物动力学的方法
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
WO2001038332A1 (en) * 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Also Published As

Publication number Publication date
EP1240903A2 (en) 2002-09-18
PA8477801A1 (es) 2000-05-24
AP2001002039A0 (en) 2001-03-31
EP1098898A1 (en) 2001-05-16
MA26660A1 (fr) 2004-12-20
IS5808A (is) 2001-01-12
IL140824A0 (en) 2002-02-10
HRP20010046A2 (en) 2002-02-28
SK285311B6 (sk) 2006-10-05
GC0000105A (en) 2005-06-29
PL345620A1 (en) 2002-01-02
ATE229964T1 (de) 2003-01-15
SV1999000096A (es) 2000-07-06
GT199900111A (es) 2001-01-05
NO20010282D0 (no) 2001-01-17
DE69904600T2 (de) 2003-11-13
EE200100038A (et) 2002-06-17
GB9815567D0 (en) 1998-09-16
US20030096795A1 (en) 2003-05-22
DK1098898T3 (da) 2003-04-07
EA200100053A1 (ru) 2001-08-27
CN1188422C (zh) 2005-02-09
JP2003521447A (ja) 2003-07-15
AU766056B2 (en) 2003-10-09
PL195736B1 (pl) 2007-10-31
ES2189450T3 (es) 2003-07-01
BG105253A (en) 2001-12-29
NO329676B1 (no) 2010-11-29
PE20000869A1 (es) 2000-09-08
DE69904600D1 (de) 2003-01-30
WO2000004033A1 (en) 2000-01-27
HUP0103432A3 (en) 2003-01-28
CA2337857A1 (en) 2000-01-27
NZ509291A (en) 2003-05-30
TNSN99145A1 (fr) 2005-11-10
KR100694721B1 (ko) 2007-03-15
BRPI9912156B1 (pt) 2016-07-26
IL140824A (en) 2004-09-27
PT1098898E (pt) 2003-04-30
TR200100111T2 (tr) 2002-02-21
CN1324363A (zh) 2001-11-28
ID28070A (id) 2001-05-03
BR9912156A (pt) 2001-04-10
HUP0103432A2 (hu) 2002-04-29
DZ2845A1 (fr) 2003-12-01
BRPI9912156B8 (pt) 2021-05-25
SK762001A3 (en) 2001-10-08
GEP20033030B (en) 2003-07-25
HK1034261A1 (en) 2001-10-19
EP1098898B1 (en) 2002-12-18
AR019388A1 (es) 2002-02-13
CO5090836A1 (es) 2001-10-30
CZ2001219A3 (cs) 2001-07-11
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
ZA200100417B (en) 2002-02-27
CZ300447B6 (cs) 2009-05-20
TWI245770B (en) 2005-12-21
JO2114B1 (en) 2000-05-21
EP1240903A3 (en) 2003-02-12
MY122323A (en) 2006-04-29
US6514953B1 (en) 2003-02-04
NO20010282L (no) 2001-03-07
EA003191B1 (ru) 2003-02-27
HU229700B1 (en) 2014-05-28
CA2337857C (en) 2011-01-25
JP3437553B2 (ja) 2003-08-18
AU5037999A (en) 2000-02-07
YU3401A (sh) 2005-06-10

Similar Documents

Publication Publication Date Title
EP1098898B1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate
EA020489B1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
US20060134190A1 (en) Formulations of bisphosphonate drugs with improved bioavailability
RU2056416C1 (ru) Производные тиомочевины, фармацевтическая композиция и способ лечения
JPH11500130A (ja) 抗ウイルス性トリアザ化合物
WO2001000635A2 (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate
CA2164296C (en) Heterocyclic chemistry
EP0028336B1 (en) Derivative of creatinol-o-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions
HK1034261B (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate
RU2256451C1 (ru) Лекарственное средство для лечения атипичной пневмонии
MXPA01000617A (en) Calcium (3s) tetrahydro-3- furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl) amino]-1-benzyl-2- (phosphonooxy) propylcarbamate
CN103864756A (zh) 丁二磺酸达比加群酯及其制备方法和用途
WO1998056781A1 (en) Form v of amprenavir (vx-478) as antiviral compound
US7001886B2 (en) Hot melt method for preparing diphenhydramine tannate
JP2003525283A (ja) ラニチジンの異形態異性体ｚ塩酸塩
JPS63295580A (ja) 骨粗鬆症治療剤
MXPA00007620A (en) Pharmaceutical compositions
JPS63297325A (ja) 骨粗鬆症治療剤